It’s the deal that no one likes. Unilever’s unsolicited proposal for GlaxoSmithKline’s consumer healthcare business has left analysts searching for any merits and questioning the logic.

They are split between denouncing the offer on the table as being too low for investors in GSK and others criticising the mooted deal itself as terrible for Unilever.